Medical Biomarkers | Medical XPRT
Articles & Whitepapers
-
Unveiling the Role of CDH1 Protein in Cancer and Future Research Directions
Introduction CDH1, also known as E-cadherin, is a crucial protein involved in cell adhesion and plays a significant role in various biological processes. In recent years, researchers have focused on understanding the functions of CDH1 and its implications in cancer development. This blog post aims to shed light on what CDH1 protein does, its role in cancer, and the future research directions in ...
-
Innovative Diagnostic Development Urges Rare Disease Therapies
Rare diseases are characterized by their low prevalence, affecting a small number of people across the world. These diseases often come with significant challenges, including accurate diagnosis, ...
News
-
VisionQuest Abstract on Diabetic Peripheral Neuropathy Accepted by ADA
We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to ...
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
Empatica partnering with U.S. Army MRDC to deploy COVID-19 early detection wearable
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays
Equipment & Solutions
-
Showcase
Technology for Early Cancer Detection
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per year over the next two decades, causing deaths to rise to 13M per year (worldwide). Annually, the worldwide economic impact of cancer is estimated by the WHO at $1.2 trillion.
Upcoming Events
-
Showcase
The 7th Global MASLD Congress
MASH/MASLD incidence rates are continuing to rise globally year after year as the disease continues to be a global health concern. Although no pharmaceutical drugs have yet received regulatory approval, there are a number of therapeutics in late phase clinical trials; case studies of which will be discussed at the congress as well as pre-clinical developments. Potential alternatives for MASH ...